Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD
Status:
Recruiting
Trial end date:
2028-10-05
Target enrollment:
Participant gender:
Summary
The proposed study will evaluate the safety and efficacy of XRT followed by systemic therapy
among patients with HER2+ metastatic breast cancer and LMD